Congress highlights
GUF 2022: CRUSE app | UCARE | Emerging research | Patient reported outcomes
CRUSE app
We analysed 620 patients from all around the world… it has been interesting to see patients with poorly controlled urticaria, with low UCT (Urticaria Control Test) scores are using the app. So there is really a need for the app. It is amazing that we now have a tool for patients to use.
UCARE
I am very excited about the many activities that UCARE is doing and has planned for the next year, we have UCARE level-up our physician education platform with many formats to come in the next year, we have UCARE for you for patients to bring new knowledge to patients which helps them in their daily lives…
Emerging research
...preterm pregnancy was associated with not controlled urticaria so it’s important to have the disease under control and to know that the treatments that were recommended by the guidelines are safe to use during pregnancy.
Patient reported outcomes
…when we asked the physician in our study of PROM [patient-reported outcome measures] use, the physician told us that they need more of an educational programme because they need to know what kind of PROM to use in chronic urticaria, how to measure this PROM and how to use these kind of PROMs. We believe that in the future all of the society/UCARE need to develop an educational PROM to teach our physician what is the best PROM to use in what kind of patient…
Is the Global Urticaria Forum 2022 meeting important for the dissemination of information on chronic urticaria?
“…we have a chance to meet with all of the physicians who are involved in the best management for our future patients. It is a good opportunity to interchange ideas about the latest management of patients with chronic urticaria. And finally, we create a family of physicians who have only one idea; how can we improve outcomes in our patients with chronic urticaria?
Hear CSU patient perspectives
Arzoo Ahmed and Elaine Dery discuss their treatment experiences, the importance of patient representatives at major congresses, such as GUF 2022 and advice for physicians managing CSU.
of interest
are looking at
saved
next event
CSU Resources and Managing CSU have been developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
The industry-sponsored symposia and eLearning have been developed in collaboration with Novartis Pharma AG, with some content provided by Novartis Pharma AG. The views presented in the videos are those of the presenters and not necessarily those of the industry sponsor, Novartis Pharma AG. Any data on non- Novartis products are based on publicly available information at the time of content update. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country.